188 related articles for article (PubMed ID: 23049908)
1. Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival.
Stein GY; Yosef N; Reichman H; Horev J; Laser-Azogui A; Berens A; Resau J; Ruppin E; Sharan R; Tsarfaty I
PLoS One; 2012; 7(9):e45969. PubMed ID: 23049908
[TBL] [Abstract][Full Text] [Related]
2. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Castro NE; Lange CA
Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
[TBL] [Abstract][Full Text] [Related]
3. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.
Locatelli A; Lofgren KA; Daniel AR; Castro NE; Lange CA
Horm Cancer; 2012 Apr; 3(1-2):14-25. PubMed ID: 22124844
[TBL] [Abstract][Full Text] [Related]
5. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.
Previdi S; Maroni P; Matteucci E; Broggini M; Bendinelli P; Desiderio MA
Eur J Cancer; 2010 Jun; 46(9):1679-91. PubMed ID: 20350802
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
8. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression.
Beviglia L; Matsumoto K; Lin CS; Ziober BL; Kramer RH
Int J Cancer; 1997 Jun; 74(3):301-9. PubMed ID: 9221809
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
10. Cooperative Effect of Oncogenic
Liu S; Li S; Wang B; Liu W; Gagea M; Chen H; Sohn J; Parinyanitikul N; Primeau T; Do KA; Vande Woude GF; Mendelsohn J; Ueno NT; Mills GB; Tripathy D; Gonzalez-Angulo AM
Mol Cancer Ther; 2019 Feb; 18(2):399-412. PubMed ID: 30518672
[TBL] [Abstract][Full Text] [Related]
11. Expression array analysis of the hepatocyte growth factor invasive program.
Cecchi F; Lih CJ; Lee YH; Walsh W; Rabe DC; Williams PM; Bottaro DP
Clin Exp Metastasis; 2015 Oct; 32(7):659-76. PubMed ID: 26231668
[TBL] [Abstract][Full Text] [Related]
12. HGF/SF-met signaling in the control of branching morphogenesis and invasion.
Zhang YW; Vande Woude GF
J Cell Biochem; 2003 Feb; 88(2):408-17. PubMed ID: 12520544
[TBL] [Abstract][Full Text] [Related]
13. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
[TBL] [Abstract][Full Text] [Related]
14. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
16. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
17. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
[TBL] [Abstract][Full Text] [Related]
18. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor/scatter factor-MET signaling in neural crest-derived melanocyte development.
Kos L; Aronzon A; Takayama H; Maina F; Ponzetto C; Merlino G; Pavan W
Pigment Cell Res; 1999 Feb; 12(1):13-21. PubMed ID: 10193678
[TBL] [Abstract][Full Text] [Related]
20. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
